.jpg?format=webp&quality=80&width=3840)
The clinical evidence base for evaluating modern type 2 diabetes interventions has expanded dramatically in recent years, with numerous efficacious treatment options available. The cardiovascular safety of these interventions has been assessed individually versus placebo in numerous cardiovascular outcomes trials (CVOTs), statistically powered to detect differences in a composite endpoint of major adverse cardiovascular events. Calibration of existing models may represent an approach to incorporating CVOT data into diabetes modelling, but this can only offer a valid comparison of one intervention versus a placebo based on a single CVOT. Ideally, model development should utilize patient‐level data from CVOTs to prepare novel risk equations that can better model modern therapies for type 2 diabetes.
Like
Save
Share